miR-125b prevent the progression of esophageal squamous cell carcinoma through the p38-MAPK signaling pathway

Chun Cheng, Qinghua Mao, Minxin Shi, Haimin Lu, Biao Shen, Ting Xiao, Aimin Yang, Yupeng Liu

Department of Thoracic Surgery, Affiliated Tumor Hospital of Nantong University, Nantong, China

Contributions: (I) Conception and design: C Cheng; (II) Administrative support: None; (III) Provision of study materials or patients: Q Mao, T Xiao; (IV) Collection and assembly of data: M Shi, A Yang, B Shen; (V) Data analysis and interpretation: H Lu, Y Liu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Yupeng Liu. Department of Thoracic Surgery, Affiliated Tumor Hospital of Nantong University, Nantong, China. Email: 16228042@qq.com.

Background: To examine the clinical significance of miR-125b in esophageal squamous cell carcinoma (ESCC) and to research the effect of miR-125b on the biological function of ESCC cells and the relevant underlying mechanism.

Methods: The expression of miR-125b in ESCC tissues and cell lines were discovered by RT-PCR assay. The interrelation between miR-125b expression and clinicopathological parameters and the forecasting of ESCC patients were analyzed. CCK-8 method and Transwell methods were used to detect the increased growth, shifting, and irruption of ESCC cells. Bioinformatics analysis was applied to forecast the possible target genes of miR-125b and verified through dual-luciferase reporter gene assay. After that, the expression of p38-MAPK mRNA and protein were found out by RT-PCR and Western blot.

Results: The expression of miR-125b was down-regulated in ESCC tissues and cell lines (P<0.05). And the expression of miR-125b was closely about tumor differentiation, TNM level, and lymph node metastasis in ESCC patients. The low miR-125b formulation was closely related to rough forecasting in ESCC patients. Large scale expression of miR-125b can effectively decrease the acceleration, shifting, and irrupting strengths of ESCC cells. Bioinformatics analysis showed p38-MAPK was forecasted to be a potential mark of miR-125b, which was confirmed by dual luciferase assay, and extreme expression of miR-125b can stop the expression of p38-MAPK mRNA and protein.

Conclusions: miR-125b is down-regulated in ESCC. Moreover, its expression level is significant concerning tumor progression and prognosis in patients with ESCC. MiR-125b can stop the high growth and shifting of ESCC cells having p38-MAPK at target.

Keywords: miR-125b; cell proliferation; esophageal squamous cell carcinoma (ESCC); p38-MAPK

Introduction

Esophageal cancer (EC) is a highly prevalent digestive system cancer, increasing incidence, and mortality rates. Although the medical treatment and surgical techniques are developed too much in the last few years, the 5-year surviving percentage of EC patients is still low. One of the factors is that patients with EC have been diagnosed at an advanced stage or have localized invasive and distant metastases. EC can be separated into a couple of pathological types: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. The occurrence of ESCC is a multi-factor, multi-step biological process, often accompanied by the dormanting of tumor-inhibiting genes and oncogenes’ activation, like STAT3, PTEN, Snail1 et al. (1,2). The expression dysregulation of these genes greatly resembles the existence and progression of ESCC, but its pathogenesis is not clear.

With the development of genetics and molecular biology,
people have a deeper understanding of the pathogenesis of ESCC. In recent years, microRNAs (miRNAs) have been implicated in tumorigenesis and tumor development. MicroRNAs are short non-coding RNAs, almost 18–25 nucleotides long, and are highly conserved (3). MiRNAs can regulate gene expression by the 3’UTR region of that particular mRNA, resulting in regulating translation suppression and/or mRNA degradation at the after-transcription stage, having relation with different life studies cell differentiation, development, and homeostasis process (4). Numerous studies have confirmed that miRNA plays a vital regulatory function in the development and progression of malignant tumors, and it resembles much to the diagnosis, treatment, and prognosis of tumor patients.

MiR-125b is examined in past ages to function as a tumor inhibitor in many cancers. In general, the outlook of miR-125b is down-regulated in tumors and plays a similar function as an oncogene, and the appearance of miR-125b is tissue specific. In different tumors comprising cells, the expression level of miR-125b is different (5), which makes miR-125b increasingly promising in the clinical testing and treatment and prognosis judgment of malignant tumors. At present, it has been found that miR-125b plays the role of oncogene or tumor suppressor gene in gastric cancer (6), liver cancer (7), colorectal cancer (8), breast cancer (9), lymphoma (10) and other malignant tumors, but its expression and regulatory role in ESCC are still unclear.

That is why this exhaustive study aimed to research the outlook of miR-125b in ESCC and its clinical benefits and study the effect of miR-125b on the biological function in ESCC development on a molecular level. The expression level of miR-125b in tumor comprising cells, some samples of ESCC was detected to analyze the interlink between miR-125b and the clinicopathological parameters and recovery as anticipated of patients with ESCC. Then cell experiments were conducted to explore the effect of miR-125b on the biological function of ESCC cells, and the potential target genes were predicted and verified by bioinformatics analysis.

We present the following article in accordance with the MDAR checklist (available at http://dx.doi.org/10.21037/jgo-20-546).

**Methods**

**Cell line**

Human ESCC KYSE410, EC-1, Eca109, TE-10, OE33 cells, and normal esophageal squamous epithelial human nonendemetrioid carcinomas (NEECs) cells were bought from ATCC, USA. ESCC cells were nourished in DMEM medium holding fetal bovine serum almost 10% and added with 100 U/mL of penicillin along with 100 µg/mL of streptomycin. NEECs were cultured in RPMI medium containing fetal bovine serum almost 10 % and placed in a CO₂ incubator at 37 °C, 5% CO₂, and cell culture medium kept changing after to 2 days of interval.

**miR-125b's detection in cells by qRT-PCR**

Total RNA was taken out from ESCC holding cells and ESCC cell lines utilizing Trizol regent, and 5µg of RNA was subjected to reverse transcription to obtain cDNA. The obtained cDNA was used as a template, and the RT-PCR reaction was conducted using SYBR Green PCR Kit. The reaction conditions around were 95 °C for 5 minutes; 40 cycles of approximately 95 °C, 30 seconds, 60 °C, 30 seconds, 72 °C, 1 minute. After the reaction was completed, the dissolution curve was drawn, and U6 was used as the internal reference. The expression of the miR-125b was then calculated by the $2^{ΔΔCt}$ method. The following primer pairs were used for the qPCR: miR-125b, forward: 5’-TCC AGT TCG GGA AGT GAA GTG A-3’, and reverse: 5’-GTC CAA AGT GGT ATT GCC ACT A-3’. GAPDH, forward: 5’-CTC CAG TAC GTA AGT GCA GAG CT-3’, and reverse: 5’-CAG TGA CAC ACG TTG CGT TGT C-3’.

**Cell transfection**

The cells were infused into all 6-well plates for 24 hours before transfecting it. When the cell fusion degree was 60% to 70%, the cells were then transfected, keeping in view the instructions given by Lipofectamine 2000 transfection reagent, and the cells were separated into four groups: miR-125b mimics, miR-125b mimics control, miR-125b inhibitor, and miR-125b inhibitor control. After transfecting it, the cells were cultured in a CO₂ incubator at 37 °C, 5% CO₂ for 48 hours for the next experiments. And RT-PCR was then used to detect transfection efficiency.

**Cell proliferation assay**

The transfected four groups of cells were made into cell suspensions, and after cell counting, $4\times10^5$ cells were seeded into plates, i.e., 96-well, and 3 of the replicate wells were set
in every group. After the cells were all attached, the CCK-8 test kit was then used to detect the absorbance at the 0, 24, 48, and 72 hours of each cell’s cell.

**Transwell assay**

Matrigel gel dissolved overnight at 4 °C was diluted 1:8 on a serum-free medium, and a Transwell chamber with an 8 µm microporous polycarbonate membrane was also put in a sterile plate of 24-well and added to the uppermost portion. The experimenter evenly spread 25 mol/L matrix gel on the bottom of the chamber, and sterile at 37 °C overnight to ensure sufficient polymerization of matrix gel. Transwell cell migration experiments were not performed with Matrigel gel. Each group of cells was collected and made into a single cell suspension. Every group of cells then was separately included in the uppermost portion of the Transwell chamber (1.5×10⁵ cells/cell), and 650 µL of RPMI (medium) containing almost 10% of the fetal bovine serum was poured to the lower chamber. Forty-eight hours, the uppermost chamber cells were thoroughly cleaned utilizing cotton swab, washed with PBS, colored with crystal violet, examined using an inverted phase (contrast) microscope (×200), photographed, and five fields were randomly observed to count the number of transmembrane cells. The experiment was done three times.

**Dual-luciferase report assay**

A search of bioinformatics websites TargetScan and miRanda showed that miR-125b has a binding place for 3’ URT of p38-MAPK, verified by dual luciferase assay, and the luciferase reporter gene was hybridized with wild-type p38-MAPK. The 3’ UTR of the mutant p38-MAPK was combined, and the miR-125b was co-transfected with the plasmid carrying the p38-MAPK target fragment for 24 hours. Detection by a multi-function microplate reader and calculating the luciferase, firefly luciferase, and value/Renilla luciferase activities, value setting three duplicate wells per sample.

**Western blotting**

The total cell protein was extracted by RPPA cell supplementation with PMSF, and protein concentration was measured by the BCA method. The experimenter took 20 protein samples for SDS-PAGE electrophoresis, and the separated protein bands were transferred to PVDF membranes, blocked with Western blocking solution for 2 hours at room temperature; then rat anti-human p38-MAPK polyclonal diluted 1:1,000 was added. Antibody (1:1,000), the internal reference GAPDH antibody was diluted 1:1,000, and reacted at 4 °C overnight; then add 1:1,000 dilution of goat anti-mouse IgG (1:5,000), react 27–30 °C for 2 hours; BeyoECL chemiluminescence Detection reagent color development, chemiluminescence color imaging, and image analysis using Quantity One software.

**Statistical analysis**

All the collected information were presented as mean ± standard deviation (x±s) utilizing SPSS19.0 statistical software. Paired t-tests were then used for comparing the two groups. The difference coming between them was statistically better at P<0.05.

**Results**

**miR-125b is shown in ESCC tissues and cell lines**

RT-PCR results proved that the relative appearance of miR-125b in ESCC tissues was significantly lower than that in adjoining normal tissues (P<0.05). Similarly, miR-125b was down-expressed in 5 ESCC cell lines equated with normal ESCC, statistically significant (Figure 1). It shows that miR-125b is downregulated in ESCC.

**Inter relation analysis between miR-125b appearance and clinicopathological parameters**

According to the median relative appearance of miR-124 in ESCC holding cells. We divided 52 patients between a very high expression category and also low expression category. The results concluded that the apparent position of miR-125b in tumor tissues was highly correlated between the strength of the invading of TNM level and lymph node metastasis, and no significant correlation with sex, age, and differentiation of tumor (Table 1).

**Interrelation analysis between miR-125b expression and patient recovery as expected**

Kaplan-Meier curve analysis for existence and survival rate was used to see the link between miR-125b appearance and recovery as predicted of patients with ESCC. The results
Figure 1 miR-125b appearance in esophageal carcinoma tissues and cells. *, P<0.05 come with NEECs; **, P<0.01 compare with normal. NEECs, nonendometrioid carcinomas.

Table 1 shows the interlink between miR-125b appearance level and clinicopathological properties in ESCC patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>miR-125b expression</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low (n=26)</td>
<td>High (n=26)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>15</td>
<td>16</td>
</tr>
<tr>
<td>Female</td>
<td>11</td>
<td>10</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>≥50</td>
<td>19</td>
<td>17</td>
</tr>
<tr>
<td>Depth of invasion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucosa</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>Submucosa</td>
<td>16</td>
<td>19</td>
</tr>
<tr>
<td>Differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Good/moderate</td>
<td>17</td>
<td>14</td>
</tr>
<tr>
<td>Poor</td>
<td>9</td>
<td>12</td>
</tr>
<tr>
<td>TNM staging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>6</td>
<td>16</td>
</tr>
<tr>
<td>III–IV</td>
<td>20</td>
<td>10</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>16</td>
<td>8</td>
</tr>
<tr>
<td>No</td>
<td>10</td>
<td>18</td>
</tr>
</tbody>
</table>

The test of Pearson chi-square acquired P value. *, P<0.05 significant statistically. ESCC, esophageal squamous cell carcinoma.
showed that ill patients with high miR-125b tend to have a longer survival period (Figure 2).

**Cell proliferation**

Eca109 cells were divided into four groups by cell transfection: miR-125b mimics, miR-125b mimics control, miR-125b binder, and miR-125b Clogger control, along with the transfection strength was verified by RT-PCR. The results concluded that the expression of miR-125b in the miR-125b mimics group was much more than the control group; on the other hand, the expression in the miR-125b Clogger group was much lesser than the control group, indicating successful transfection. The proliferation of transfected cells at the 0, 24, 48, and 72 hours was detected by the CCK8 method. The results concluded that miR-125b mimics cells' proliferation activity was much downsized from the 48th hour, while the proliferation activity of miR-125b Clogger group cells was much elevated (Figure 3), showing that miR-125b can clog the proliferation of the ESCC cells.

**Transwell assay for cell migration and invasion**

The Transwell cell migration assay outcome concluded that the number of transmembrane cells in the miR-125b mimics group was lesser than in miR-125b mimics control group transmembrane cells among the miR-125b clogger group was more than that in the miR-125b inhibitor control group (Figure 4A). Similarly, the Transwell cell invasion assay showed that after transfection of the miR-125b mimics, the percentage of Eca109 transmembrane cells in ESCC cells was downsized transmembrane cells transfected with miR-125b was much elevated (Figure 4B). It shows that miR-125b can inhibit the shifting and occupy of ESCC cells.

**Dual-luciferase assay for miR-125b targeting p38-MAPK**

Bioinformatics software analysis revealed a binding place for the miR-125b and p38-MAPK (Figure 5A). The outcome of dual-luciferase assay concluded that the relative fluorescence intensity of p38-MAPK in miR-125b mimics transfection group was lesser than in the control group (P<0.01), and the miR-125b binding site in p38-MAPK 3’UTR was also changed/mutated (Figure 5B). The clogging effect of the miR-125b over the reporter gene disappeared, showing that that miR-125b can act on 3’UTR of p38-MAPK messenger RNA directly to stop the expression of p38-MAPK.

**Outcome of the miR-125b on p38-MAPK mRNA and protein appearance**

RT-PCR results concluded that the expression of p38-MAPK mRNA was downsized after more expression of miR-125b, while p38-MAPK mRNA level was raised after clogging of miR-125b expression, statistically significant (P<0.05); The outcomes of Western blotting indicated that the appearance of p38-MAPK protein in miR-125b mimics group was decreased, while the expression of the p38-MAPK protein in miR-125b inhibitor group had dropped significantly (P<0.05) (Figure 6).

**Discussion**

ESCC progression is a complex process involving multiple gene regulation and multiple steps. It is of huge clinical use to understand the mechanism of ESCC development and improve the initial stage diagnosis of ESCC and improve patients’ recovery expectations. MicroRNAs (miRNAs) are a category of small chain non-coding RNA molecules that are about 18–25 nucleotides inhibit length. By binding with
the 3′ UTR site of a particular microRNA, and miRNAs cause mRNA degradation, inhibit protein translation, and regularizes gene showing after the transcriptional stage. Presently, several miRNAs have been found out, most of which are present in cells and have various biological functions such as regulating cell differentiation, development, and homeostasis. Studies found that most of the miRNAs are located in tumor-associated chromosomal sites, participate in regularizing transcriptional expression of tumor-associated genes, and thus participate in DNA damage of tumor cells, regulate the cell cycle, apoptosis and change the tumor microenvironment (11). In tumorigenesis and development, miRNAs play the role of oncogenes or tumor suppressor genes. Earlier studies have reported that more than 30% of human genes regulated with miRNAs aid (12), but the molecular process involved in regulating miRNAs is still largely unclear. MicroRNAs are tissue-specific, conserved, and time-series, making miRNAs have great clinical potential and can serve as potential markers for cancer diagnosis, therapeutic evaluation, and prognosis.

miR-125b is a part of the miR-125 (family) residing in chromosome 21, which is affiliated with differentiation, proliferation, apoptosis, occupying, metastasis, and malignant cells’ drug resistance containing tumor (13). The expression of that miR-125b is tissue-specific, and miR-125b exerts different regulatory functions in different tumor tissues, such as bladder cancer, breast cancer, hepatocellular carcinoma, and ovarian cancer, melanoma, and osteosarcoma. And below-regulation of miR-125b exerts a tumor-suppressing effect, while in pancreatic cancer and prostate cancer, the expression of miR-125b is much higher than that of neighboring normal tissues and does a function in promoting cancer progression (14). Panella et al. found that the expression of miR-125b was

**Figure 3** Cell growth curve of ESCC cells. (A) Relative appearance of miR-125b in various transfection groups; (B) growth curve of ESCC cells in different transfection groups. *, P<0.05 vs miR-125b mimics. ESCC, esophageal squamous cell carcinoma.
regulated less in hepatocarcinoma containing cells and hepatocellular carcinoma cell lines, and the proliferation along with metastasis of hepatoma cells could be inhibited by targeting the oncogene lin28 (15). By overexpressing miR-125b in cancer cell SKBR3 of the breast, Vilquin et al. found that the appearance of ERBB2 and ERBB3 protein was decreased, and the proliferation ability of breast cancer cells was inhibited (16). Aherne et al. found that miR-125b was hijacked in prostate cancer cells. In androgen receptor prostate cancer cell lines LNCAP and CDs, androgen can develop the buildup of cancer cells of prostate by up-regulating miR-125b (17). The above studies reveal that miR-125b does indispensable regulatory work in developing various tumors, but its research in ESCC is still rare.

P38MAPK among the four major signaling pathways having a hand in MAPKs. Extracellular stimuli such as bacterial pathogens and cytokines activate the simultaneous phosphorylation of the Tyr and Tyr double sites of p38MAPK, and the activated p38MAPK transduces signals to Nuclei initiate transcription of related target genes and also transduce signals to other cellular components to produce different cellular responses (18). P38MAPK involves a huge scale biological process, i.e., promoting apoptosis, working in inflammatory reactions, ischemia-reperfusion injury, promoting cell phenotype transdifferentiation, and targeting a variety of different proteins (19). Activation of p38MAPK signaling pathway and manufacturing of pro-inflammatory cytokines [for instance interleukin (IL-1β), IL-6, Tumor Necrosis Factor-α (TNF-α)], induction of Cyclooxygenase 2 (COX-2), expression of nitric oxide synthase (infusible NOS) and intercellular adhesive molecule-1 (ICAM-1) is closely related (20). Recent studies have displayed that p38MAPK is highly expressed in breast cancer, prostate cancer, showing that it may be related to tumorigenesis and development. Chen et al. found that miR-3188 can target p38MAPK to inhibit outgrowth migration and invading breast cancer cells (21). Hu et al. found that activation of the p38MAPK
signaling pathway in pancreatic cancer can increase tumor cells’ proliferative ability and promote peripheral blood vessels (22).

Here we first saw the expression percentage of miR-125b in ESCC tissues of the tumor. It was found that the level of expression of miR-125b in the tumor tissues was lesser than that in bordering normal tissues, and the decreased expression of miR-125b and the depth of tumor infiltration, TNM staging was relating to lymph node metastasis. The prognostic study showed that the survival period of miR-125b high expression was well higher than that of miR-125b low-level expression, indicating that miR-125b expression affects the degree of the continuity of disease and recover forecasted in patients with ESCC. Furthermore, the expression level of miR-125b in ESCC cell lines was determined by RT-PCR. The results gave
the lesson that the expression of miR-125b was down-regulated in five ESCC cell lines, which was regular with the results detected in tumor tissues, indicating that miR-125b is down-regulated in ESCC. The expression of miR-125b in ESCC cell line Eca109 was successfully regulated by cell transfection. The proliferation, migration, and invasion ability of ESCC cells were discovered by the CCK-8 method and the Transwell method. The results showed that large-level expression of miR-125b, the accumulation/elevation, migration and entry, and invasion of ESCC cells decreased greatly, indicating that miR-125b can inhibit the proliferation, migration, and invasion of ESCC cells. MiR-125b plays a similar role as a tumor stopping gene. Bioinformatics predicts that p38-MAPK may be a targeting gene of miR-125b. Dual-luciferase results show that miR-125b has a focused targeting effect on p38-MAPK, and big scale expression of miR-125b can block p38-MAPK mRNA. And protein expression, showing that miR-125b has the quality to regulate the ESCC cells by p38-MAPK signaling pathway.

While summing up this discussion, the expression of miR-125b is down-regulated in the ESCC, and its expression strength is closely related to the depth of the invasion of the tumor, TNM level lymph node metastasis, and prognosis. miR-125b has this feature of stopping the proliferation, shifting, and invasion of ESCC cells by having a target p38-MAPK signaling pathway, which plays a similar role as a tumor suppressor gene.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the MDAR checklist. Available at http://dx.doi.org/10.21037/jgo-20-546

Data Sharing Statement: Available at http://dx.doi.org/10.21037/jgo-20-546

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jgo-20-546). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


(English Language Editor: J. Chapnick)